Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03

Background: Triple negative breast cancer (TNBC) patients with residual disease after neoadjuvant chemotherapy (NAC) face high risk of recurrence. BREASTIMMUNE-03 trial evaluates the efficacy of nivolumab and ipilimumab combination compared to capecitabine as adjuvant treatment. Methods: This multic...

Cur síos iomlán

Sonraí bibleagrafaíochta

Príomhchruthaitheoirí:	Olivier Trédan, Delphine Loirat, Sylvie Chabaud, Philippe Toussaint, Thierry Petit, Frédéric Viret, Christelle Levy, Aurélien Robert, Julien Grenier, Laura Mansi, Jean-Philippe Spano, Anne Patsouris, Olfa Derbel, Christelle Jouannaud, Jean Marc Ferrero, Jean Sébastien Frenel, Yann Molin, Louis Doublet, Pierre-Etienne Heudel, Jean-Yves Pierga, Gwenaële Garin, David Pérol, Thomas Bachelot
Formáid:	Artigo
Teanga:	Inglês
Foilsithe / Cruthaithe:	Elsevier 2026-02-01
Sraith:	Breast
Ábhair:	TNBC Immunotherapy Immune checkpoint inhibitors Nivolumab Ipilimumab Capecitabine
Rochtain ar líne:	http://www.sciencedirect.com/science/article/pii/S0960977625008653
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!